Media headlines about Shire (NASDAQ:SHPG) have been trending somewhat positive on Tuesday, according to Accern. Accern ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Shire earned a daily sentiment score of 0.05 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 46.0086198860122 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s analysis:
- What’s Happening With These Drug Makers Stocks? — Immune Pharmaceuticals, Zogenix, Shire, and Merck – PR Newswire (press release) (prnewswire.com)
- Comparing Immune Pharmaceuticals (IMNP) and Shire (SHPG) (americanbankingnews.com)
- Shire plc : Director Declaration (finance.yahoo.com)
- Shire says Hunter syndrome treatment fails in key study (finance.yahoo.com)
- Shire’s stock falls after drug trial misses primary and secondary endpoints (finance.yahoo.com)
Several research firms recently issued reports on SHPG. Royal Bank of Canada reaffirmed a “buy” rating and issued a $213.00 price objective on shares of Shire in a research report on Monday, October 2nd. Cantor Fitzgerald set a $222.00 price target on Shire and gave the company a “buy” rating in a report on Tuesday, December 5th. FBR & Co reissued a “buy” rating and set a $201.00 price target on shares of Shire in a report on Monday, October 30th. Liberum Capital raised Shire from a “hold” rating to a “buy” rating in a report on Tuesday, November 14th. Finally, ValuEngine raised Shire from a “hold” rating to a “buy” rating in a report on Thursday, October 26th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $212.18.
Shire (NASDAQ:SHPG) last released its quarterly earnings results on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share for the quarter, beating the consensus estimate of $3.64 by $0.17. The firm had revenue of $3.70 billion for the quarter. Shire had a return on equity of 14.41% and a net margin of 10.95%. Shire’s quarterly revenue was up 7.1% compared to the same quarter last year. During the same period in the previous year, the company earned $3.17 earnings per share. analysts expect that Shire will post 15 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This piece was first published by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece on another site, it was copied illegally and reposted in violation of international copyright law. The correct version of this piece can be viewed at https://www.com-unik.info/2017/12/19/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-shire-shpg-share-price.html.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.